Avenue Therapeutics (ATXI) AI Stock Analysis

• Market Cap: $1.48M
• Dividend Yield: N/A
• Average Volume (3M): 2.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: N/A
• EPS Growth: 89.68%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 3,294,635
• 10 Day Avg. Volume: 2,401
• 30 Day Avg. Volume: 2,901
• PEG Ratio: -0.22
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 1.52
• P/FCF Ratio: -1.16
• Enterprise Value/Market Cap: -0.93
• Enterprise Value/Revenue: -0.98
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.42
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $0.36 ▼(-51.37% Downside)
• Action: Reiterated Date: 03/31/26
• Date: Action: Reiterated 03/31/26

The score is held back primarily by ongoing losses, negative cash flow, and a limited balance-sheet base despite improving year-over-year results and no debt. Technicals are moderately supportive in the near term (above 20/50-day with positive MACD) but still weak on longer-term trends and show an overextended stochastic. Valuation support is limited due to negative earnings and no dividend, while the ATX-04 licensing event provides a constructive catalyst that partially offsets fundamental risk.

Positive Factors

Zero debt / conservative leverage

A zero-debt capital structure materially lowers fixed financing obligations and interest risk, improving financial flexibility. For an early-stage biotech, this conservatism preserves the ability to negotiate partnerships or dilute strategically without the added strain of debt servicing on limited cash flows.

Negative Factors

Ongoing negative cash generation

Persistent negative operating and free cash flow indicate the business cannot finance development from internal sources. Over time this pattern requires repeated external capital, raising dilution and execution risk, and constrains long-term planning for multi-stage clinical programs.

Avenue Therapeutics Business Overview & Revenue Model

Company Description

Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, whi...

Read more

Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, whi...

How the Company Makes Money

null...

Avenue Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.40M	0.00	0.00	0.00	0.00
Gross Profit	1.40M	0.00	0.00	0.00	0.00
EBITDA	-3.29M	-11.70M	4.05M	-2.44M	7.00K
Net Income	-2.91M	-11.65M	-10.38M	-3.55M	-3.73M
Balance Sheet
Total Assets	2.93M	2.67M	1.85M	6.84M	3.96M
Cash, Cash Equivalents and Short-Term Investments	2.85M	2.59M	1.78M	6.71M	3.76M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.10M	816.00K	1.20M	3.58M	509.00K
Stockholders Equity	1.83M	2.80M	1.58M	3.90M	3.45M
Cash Flow
Free Cash Flow	-1.83M	-9.03M	-12.45M	-7.60M	-3.75M
Operating Cash Flow	-1.83M	-9.03M	-9.45M	-7.60M	-3.75M
Investing Cash Flow	0.00	0.00	-3.00M	0.00	0.00
Financing Cash Flow	2.09M	9.84M	7.53M	10.54M	4.38M

Avenue Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.73
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Positive. The current price of 0.73 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.24, and above the 200-day MA of 0.53, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 72.74 is Negative, neither overbought nor oversold. The STOCH value of 84.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXI.

Avenue Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATXI	53 Neutral	$1.48M	-0.73	-121.42%	―	―	89.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	44 Neutral	$2.05M	―	―	―	178.82%	-4121.10%
BDRX	43 Neutral	$1.47M	-0.07	-63.03%	―	-100.00%	86.75%
OGEN	―	$2.69M	-0.17	-168.95%	―	―	90.27%

Avenue Therapeutics Corporate Events